Amisulpride and neuroleptic malignant syndrome

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Medicine

Background:

• Neuroleptic malignant syndrome (NMS) is a rare, life-threatening condition associated with antipsychotic medications.
• Amisulpride, a second-generation antipsychotic, has been linked to NMS, though its presentation can be atypical.

Observation:

• This study details the first reported case of amisulpride-induced NMS in Taiwan.
• The case exhibited atypical NMS features, including less pronounced hyperthermia and elevated creatine kinase levels compared to typical NMS.
• The Naranjo scale categorized the association between amisulpride and NMS as 'probable'.

Findings:

• Second-generation antipsychotics like amisulpride may induce atypical NMS with subtle clinical signs.
• Subtle presentations of NMS can complicate early diagnosis and intervention.
• Dopamine receptor blockade is the suspected, though not fully understood, mechanism behind NMS.

Implications:

• Increased awareness of atypical NMS presentations associated with amisulpride is crucial for timely diagnosis.
• Further research into the pathogenesis of amisulpride-induced NMS may improve patient outcomes.
• Clinical vigilance is necessary to detect NMS, especially when using newer antipsychotics with atypical symptom profiles.